Yuyu Pharma has announced that it made a 1.24 billion won investment in the U.S. animal drug development company "Vetmab Biosciences" for the pet-only community service "Dog PPL" (DOG PPL) on the 9th. Vetmab is a veterinary biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for dogs and cats. Dog PPL is a membership community service exclusive to pet dogs, established in Los Angeles (LA), U.S., in 2021. By paying a membership fee, users can access facilities such as dog parks, cafes, events, bars, and lounges. To sign up, users must submit their pet's vaccination status and other information.
ST PHARM will participate in the "CRISPR Medicine 2025" conference, specialized in gene editing therapies, taking place in Copenhagen, Denmark, from the 7th to the 11th (local time), to promote its technology. At this conference, ST PHARM will present three poster presentations showcasing "STLNP," which improves efficiency and safety compared to existing lipid nanoparticles (LNP), and the "SmartCap" mRNA molecular stabilization technology.
The molecular diagnostic corporation Seegene will showcase a video introducing its diagnostic system "Cureka," which automates the entire process of polymerase chain reaction (PCR) testing, at the European Congress of Clinical Microbiology and Infectious Diseases (ESCMID) held in Vienna, Austria, from the 11th to the 15th. In July, the physical product of Cureka will be unveiled. Cureka is a next-generation diagnostic system that can automatically test all PCR specimens.
Lunit noted on the 8th that research results on interactions between healthcare professionals and AI have been published in the international journal "Radiology" of the Radiological Society of North America (RSNA). A research team from Sweden's largest private hospital, "Capio S:t Göran Hospital," conducted a detailed analysis of interaction scenarios between specialists in radiology and the AI image analysis solution for mammography, "Lunit Insight MMG," using data from approximately 55,000 women who underwent breast cancer screenings. After independent readings by two specialists and the AI, if any of the three suspected cancer, a consensus discussion was held. As a result, when one specialist suspected cancer alone, the recall rate for additional testing was 14.2%, higher than the 4.6% recall rate when the AI suspected cancer alone. However, the positive predictive value (PPV), indicating the rate at which cancer was actually found among recalled patients, was 3.4% when suspected by a specialist alone, lower than the 22% PPV when the AI suspected cancer.
The Ministry of Health and Welfare and the Korea Health Industry Development Institute will hold a business briefing for the "Biohealth Academy" project on the 17th at 2 p.m. at the B&D Partners conference room in Samseong-dong, Seoul, to cultivate talent in the biohealth industry. The Biohealth Academy project, which is being launched for the first time this year, will select five operating institutions to support the planning and operation of talent development programs. Pharmaceutical and medical device corporations interested in participating can apply through the Institute's website (www.khidi.or.kr).
The Ministry of Food and Drug Safety announced on the 9th that it approved 129 medical product items in March. This number refers to items approved by the headquarters, excluding those approved by local food and drug safety administrations, with 38 items in pharmaceuticals, 2 in quasi-drugs, and 89 in medical devices. Among the approved new drugs are the migraine preventive treatment "NuTec Orally Disintegrating Tablets 75 mg (Limezepant Sulfate Hydrate)" and the treatment for adult patients with metastatic colorectal cancer "Frucaclacapsule 1 mg (Pralsetinib)." Additionally, it approved a digital medical device, the software "DeepFore Recur," which assists in diagnosing hepatocellular carcinoma by indicating the probability of recurrence, making it the first approval of its kind in the country.
Dong-A Pharmaceutical will collaborate with the Chinese gaming company Hoyoverse on "Bacchus-flavored jelly." The packaging of Bacchus-flavored jelly will feature popular characters from the game "Genshin Impact," and a "Genshin Seal" containing random codes for 30 types of Genshin characters and game items will also be provided. The collaborative product will be available at convenience stores nationwide starting mid-month and will also be sold along with collaboration goods at Dong-A Pharmaceutical's official online mall and Naver Brand Store beginning on the 16th.